Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Eugia Pharma receives USFDA approval for Icatibant Injection

    Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

  • Lupin Receives approval from USFDA for Metoprolol Succinate Extended-Release Tablets USP
    Lupin Receives approval from USFDA for Metoprolol Succinate Extended-Release Tablets USP

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

  • FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions
    FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

    The Food and Drug Administration granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

  • Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
    Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis

    Bristol Myers Squibb has launched Clear Understanding, a campaign featuring patients living with moderate to severe plaque psoriasis who are sharing what it’s really like for them to live with the disease from dealing with symptoms to navigating relationships with friends, family or co-workers to dispelling misconceptions about the condition.

  • Novartis Completes acquisition of Chinook Therapeutics
    Novartis Completes acquisition of Chinook Therapeutics

    Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.

  • Show cause notices issued to 143 pharma firms after inspections
    Show cause notices issued to 143 pharma firms after inspections

    The Central Drugs Standard Control Organisation along with state licensing authorities has conducted risk-based inspections of 162 pharmaceutical firms and issued show-cause notices in 143 cases, Union Health minister Mansukh Mandaviya said on Tuesday.

  • IIHMR University inaugurates MBA programme 2023-25
    IIHMR University inaugurates MBA programme 2023-25

    IIHMR University, Jaipur, organised an Inauguration ceremony of newly admitted students of MBA (Hospital and Health Management), MBA (Pharmaceutical Management) and MBA (Development Management) programmes, 2023-25, at its campus.

  • CDSCO issued show-cause notices to various epharmacy companies
    CDSCO issued show-cause notices to various epharmacy companies

    Central Drugs Standard Control Organization (CDSCO) has issued show- cause notices to various firms engaged in online/internet sale of Drugs on 8th & 9th February 2023.

    The firms have mostly responded by stating that they are only providing an online platform for facilitating the sale of pharmaceutical products to customers and the platform operates solely as intermediaries, connecting the users and the licensed pharmacies.

  • Lilly Completes Acquisition of DICE Therapeutics
    Lilly Completes Acquisition of DICE Therapeutics

    Eli Lilly and Company announced the successful completion of its acquisition of DICE Therapeutics, Inc  The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

  • Parliament passes the Anusandhan National Research Foundation (NRF) Bill, 2023
    Parliament passes the Anusandhan National Research Foundation (NRF) Bill, 2023

    Union Minister for Science & Technology Dr Jitendra Singh said here today that "Anusandhan National Research Foundation" will define the stature of India at 2047. Replying to the discussion on "Anusandhan National Research Foundation (NRF) Bill, 2023" in the Rajya Sabha, Dr Jitendra Singh said, the Anusandhan Act will pave the way for India to join the select league of developed nations.

Subscribe to Pharma News